an old exerpt from a Edison report...AIPAC data expected H219The AIPAC Phase IIb breast cancer study is over 70% recruited, with enrolment reaching 160 out of the target of 226 as of the AGM on 16 November. Recruitment passed the halfway mark (113/226) in June and reached 126 (56%) in early August. The company expects recruitment to continue into H119, and the event-driven PFS readout to report in H219 (after 152 PFS events).
The trial is testing the efti soluble LAG-3 fusion protein combined with paclitaxel in women with hormone receptor positive metastatic breast cancer who have not previously received chemotherapy for metastatic disease. The European Medicines Agency has indicated that this trial could be sufficient to support a marketing authorization if it achieves certain (undisclosed) clinical endpoints. A confirmatory Phase III study would likely be required before filing for approval in the US.
LAG-3, page-9
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $435.7M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 29.5¢ | $399.6K | 1.329M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 13902 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 29836 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |